Volume 1, Issue 1, Pages 2-8 (May 2019)

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

Volume 60, Issue 1, Pages (January 2014)
Volume 63, Issue 1, Pages (July 2015)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Volume 32, Issue 2, Pages (February 2000)
The impact of hepatitis E in the liver transplant setting
Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease  Karl Heinz Weiss, Florentine Thurik, Daniel Nils Gotthardt, Mark Schäfer,
Hepatic Disease of Horses in the Western United States
Volume 122, Issue 4, Pages (April 2002)
Inflammasomes in liver diseases
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Volume 117, Issue 1, Pages (July 1999)
The New England Journal of Medicine (378;12) March 22, 2018
Lipids in Liver Disease: Looking Beyond Steatosis
Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C  C. Sagnelli, M. Merli, C. Uberti-Foppa, H. Hasson,
The impact of hepatitis E in the liver transplant setting
T. Vescovo, G. Refolo, G. Vitagliano, G.M. Fimia, M. Piacentini 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Non-invasive diagnosis of non-alcoholic fatty liver disease
Leptin, obesity, and liver disease
Stem cell therapies for liver failure and cirrhosis
Nonalcoholic steatohepatitis
Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment- Naïve Patients With Chronic Hepatitis C  Albert Friedrich Stättermayer,
Grand Rounds: Alcoholic Hepatitis
Senescence: Not Just for Tumor Suppression
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Peter R. Mueller-Abt, Kieran J. Frawley, Ristan M. Greer, Peter J
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease  Karl Heinz Weiss, Florentine Thurik, Daniel Nils Gotthardt, Mark Schäfer,
European Association for the Study of the Liver  Journal of Hepatology 
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Diagnostic Value of Quantitative Hepatic Copper Determination in Patients With Wilson’s Disease  Peter Ferenci, Petra Steindl-Munda, Wolfgang Vogel, Wolfgang.
Effects of rosuvastatin (added to hypocaloric diet) on serum periostin, adiponectin, proinflammtory cytokines levels and hepatic steatosis in non-alcoholic.
Acute-on chronic liver failure
What is the long-term outcome of the liver allograft?
Trends in the management and burden of alcoholic liver disease
Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 146, Issue 5, Pages (May 2014)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Volume 140, Issue 4, Pages e1 (April 2011)
Viral Hepatitis in Liver Transplantation
E.C. Böttger  Clinical Microbiology and Infection 
Volume 116, Issue 1, Pages (January 1999)
EASL Clinical Practice Guidelines: Wilson’s disease
Wilson Disease Mayo Clinic Proceedings
Cannabinoid signaling and liver therapeutics
Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis.
Senescence in chronic liver disease: Is the future in aging?
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
NASH animal models: Are we there yet?
Volume 50, Issue 3, Pages (March 2009)
Volume 64, Issue 6, Pages (June 2016)
Volume 44, Issue 5, Pages (May 2006)
Lipids in Liver Disease: Looking Beyond Steatosis
Volume 63, Issue 1, Pages (July 2015)
Tatiana Kisseleva, David A. Brenner  Journal of Hepatology 
Volume 142, Issue 6, Pages e4 (May 2012)
Volume 65, Issue 4, Pages (October 2016)
Approaches for patients with very high MELD scores
Volume 1, Issue 1, Pages 9-16 (May 2019)
Volume 64, Issue 2, Pages (February 2016)
The metabolomic window into hepatobiliary disease
Volume 125, Issue 4, Pages (October 2003)
Volume 61, Issue 2, Pages (August 2014)
Controversies in Liver Transplantation for Hepatitis C
Exercise in Individuals With CKD: A Focus Group Study Exploring Patient Attitudes, Motivations, and Barriers to Exercise  Jessica Kendrick, Michael Ritchie,
Volume 1, Issue 1, Pages (May 2019)
Presentation transcript:

Volume 1, Issue 1, Pages 2-8 (May 2019) HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson’s Disease  Peter Ferenci, Jan Pfeiffenberger, Albert Friedrich Stättermayer, Rudolf E. Stauber, Claudia Willheim, Karl H. Weiss, Petra Munda- Steindl, Michael Trauner, Michael Schilsky, Heinz Zoller  JHEP Reports  Volume 1, Issue 1, Pages 2-8 (May 2019) DOI: 10.1016/j.jhepr.2019.02.007 Copyright © 2019 The Author(s) Terms and Conditions

JHEP Reports 2019 1, 2-8DOI: (10.1016/j.jhepr.2019.02.007) Copyright © 2019 The Author(s) Terms and Conditions

Fig. 1 HSD13B17:TA allele frequency according to phenotypic presentation in 584 patients with Wilson’s disease. **p <0.001 vs. non-fulminant liver disease, *p <0.05 vs. neurologic presentation JHEP Reports 2019 1, 2-8DOI: (10.1016/j.jhepr.2019.02.007) Copyright © 2019 The Author(s) Terms and Conditions

Fig. 2 HSD13B17:TA allele frequency according to liver histology at diagnosis in 404 patients with Wilson’s disease. Patients with F2-F3 were combined as advanced liver disease (25 has also marked steatosis), those with F0-1 as mild liver disease (20 were F0 with minimal steatosis and 49 with marked steatosis with F0-F1). CH= chronic hepatitis like picture, none had signs of advanced fibrosis or fat accumulation. *p = 0.02 vs. advanced fibrosis/cirrhosis JHEP Reports 2019 1, 2-8DOI: (10.1016/j.jhepr.2019.02.007) Copyright © 2019 The Author(s) Terms and Conditions

Fig. 3 Schematic presentation of the potential action of HSD17B13 on the evolution of fulminant Wilson’s disease. A primary trigger for liver injury leads to hepatocellular necrosis resulting in the release of copper. The increase of copper concentration in serum leads to destruction of erythrocytes, and together with copper in in the extracellular liver tissue to further death of hepatocytes. This cycle of events may ultimately lead to liver failure. We assume that HSD17B23:TA may protect hepatocytes. JHEP Reports 2019 1, 2-8DOI: (10.1016/j.jhepr.2019.02.007) Copyright © 2019 The Author(s) Terms and Conditions